Search
omecamtiv mecarbil
Indication:
- systolic heart failure
- left ventricular systolic dysfunction
* in addition to standard systolic heart failure treatment
* well tolerated, may be of benefit [2]
Dosage:
- 25 mg, 37.5 mg, or 50 mg twice dailyt
Mechanism of action:
- selective cardiac myosin activator
General
cardiovascular agent
References
- Teerlink JR, Diaz R, Felker GM et al
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
N Engl J Med. 2020 Nov 13.
PMID: 33185990
- Felker GN, Solomon CD, Claggett B et al
Assessment of Omecamtiv Mecarbil for the Treatment of Patients With
Severe Heart Failure. A Post Hoc Analysis of Data From the GALACTIC-HF
Randomized Clinical Trial.
JAMA Cardiol. 2022;7(1):26-34
PMID: 34643642 PMCID: PMC8515258 (available on 2022-10-13)
https://jamanetwork.com/journals/jamacardiology/fullarticle/2785151